Combination treatment for relapsed or refractory large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests combining three medicines (lisaftoclax, chidamide, and rituximab) to see if they help people whose large B-cell lymphoma has returned or not responded to previous treatments. The goal is to find a new option for patients who cannot have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or hasn't responded to previous treatment.
- Your lymphoma cells show a protein called BCL-2 (found in many lymphomas) in at least 30% of the cells.
- You received at least one earlier treatment (like chemotherapy or antibody therapy), but it wasn't enough, and you are not eligible for a stem cell transplant using your own cells.
- You have at least one measurable sign of lymphoma (like a lymph node or tumor) that can be checked during the study.
- Your bone marrow, liver, and kidneys are working well enough, and you are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
This trial tests a new drug called lisatoclax added to the usual chemotherapy and antibody treatment for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL). The goal is to see if adding this drug helps the standard treatment work better.
This trial tests a new combination of three drugs for people recently diagnosed with a type of lymphoma called large B-cell lymphoma. The goal is to see if this combination is safe and effective, and it might offer a new treatment option.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of three drugs (golcadomide, poseltinib, and rituximab) for people with a type of lymphoma that has returned or not responded to previous treatment. The goal is to see if this combination is safe and effective for those who cannot have a stem cell transplant.
This trial tests a new combination of two targeted drugs (lisaftoclax and acalabrutinib) against standard chemo-immunotherapy for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment. It aims to see if the combination works better.
Hear when a new Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.